They hold a monopoly on the one process HBM can't exist without, yet the street is obsessed with a China fade.
Thesis: Lam is the gatekeeper of HBM. You cannot stack DRAM without Through-Silicon Vias (TSVs), and Lam has 100% share of that step. While the Street hand-wrings over China normalizing from 40% of revenue, they are missing the margin accretion from the mix shift toward advanced packaging. The cycle bottom is in, lead times have normalized, and they are aggressively investing while competitors cut. This is a structural winner disguised as a cyclical recovery play.
Verdict: LONG — Conviction: HIGH
Catalyst: The 'second half weighted' recovery turning into explicit HBM-driven backlog expansion, forcing analysts to re-rate 2025 earnings power beyond cyclical norms.
Key Risk: China revenue (40%) drops faster than the HBM/DRAM recovery ramps, creating a temporary air pocket in revenue and margin compression before the structural thesis plays out.
The Tell: When asked if China declines while core DRAM rises, Bettinger simply said 'Probably.' No spin, no 'we expect balanced growth.' Just a blunt admission that the China tailwind is flipping to a headwind.
Friction Level: MODERATE_FRICTION — Bulls see HBM monopoly driving a structural margin step-up. Bears see a China revenue cliff (40% to normalized) that HBM growth can't fully offset in the near term.
Report not found
The report data is no longer available. Please return to the archive.